A Study of LY2835219 in Japanese Participants With Advanced Cancer
NCT02014129
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm Metastasis
Lymphoma
Interventions
DRUG:
LY2835219
Sponsor
Eli Lilly and Company